11 partners from 4 countries

Developing an innovative immunotherapeutic approach, based on mRNA-loaded lipid nanoparticles, to eliminate intra- and extracellular bacteria. Using tuberculosis as a proof of concept, NanoBiCar aims to revolutionize the treatment of bacterial infections, providing a safe, cost-effective, and resistance-free alternative, suitable for high-burden and low-resource settings.